When the barrier to entry is that high, it basically guarantees that only mega-corporations get to decide what treatments see the light of day
prescription drugs by sales are largely expensive, specialized therapies (often biologics) for serious chronic illnesses (cancer, diabetes/obesity, autoimmune disease, etc.)
For certain experiments, researchers may seek out BPC-157 prepared as an acetate salt, which is generally considered more biocompatible for in-vitro use, although potentially less stable
Top stacking candidates include BPC-157 for gut health and tissue healing, TB-500 for systemic recovery, GHK-Cu for skin tightening and collagen support, and Tesamorelin for enhanced fat metabolism
The Nature Medicine fatty liver trial made the same point: 8 mg achieved 81 percent liver fat reduction, 12 mg achieved 82 percent